Visual Abstract

Type 1 diabetes (T1D) can lead to significant emotional distress and impair quality of life (QoL). Hybrid closed-loop (HCL) technology seeks to relieve this burden, a goal with equal importance to improving glycemic outcomes. We evaluated change in QoL outcomes for children (6.0-11.9y) and teens (12.0-17.9y) with T1D and their parents/guardians before and after a 3-month study of HCL therapy with the Omnipod 5 System. Validated assessment tools administered included diabetes-related QoL (PAID and HCS) and generic QoL (PSQI and WHO-5) questionnaires. Children (n=83) and teens (n=42) were (mean±SD): age 9±2y and 14±2y, with T1D duration 4±2y and 7±3y and A1C 7.5±0.9% and 7.9±1.0%, respectively. Responses revealed significantly reduced diabetes distress for all groups (Table). Also, parents of children reported significant improvement in overall well-being (WHO-5), hypoglycemic confidence (HCS) and in 3 PSQI sleep subscales: quality (change: ‑0.43±0.83, p<0.01), disturbance (‑0.18±0.58, p<0.01), and duration (‑0.28±1.00, p<0.01). In this 3-month study, the Omnipod 5 System reduced diabetes distress for youth and their parents. The most striking improvements in QoL were seen in parents of children, a group in great need of solutions to help them care for their children without negatively affecting their own QoL.

graphic
View largeDownload slide
Disclosure

K. K. Hood: Consultant; Self; Cecelia Health, Cercacor, LifeScan Diabetes Institute. W. H. Polonsky: Advisory Panel; Self; Intarcia Therapeutics, Inc., Consultant; Self; Abbott Diabetes, ADOCIA, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Novo Nordisk, Onduo LLC., Sanofi US. S. A. Macleish: Advisory Panel; Self; Insulet Corporation. C. J. Levy: Advisory Panel; Self; Dexcom, Inc., Eli Lilly and Company, Employee; Spouse/Partner; AbbVie Inc., Other Relationship; Self; Dexcom, Inc., Research Support; Self; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation.

Funding

Insulet Corporation

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.